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Abstract 
Background: The relationships between morbid obesity, changes in body mass index 
(BMI) prior to cancer diagnosis, and lung cancer outcomes by histology (small-cell lung 
cancer (SCLC) and non-SCLC (NSCLC)) have not been well studied. 
Methods: Individual level data analysis was performed on 25,430 NSCLC and 2,787 
SCLC patients from sixteen studies of the International Lung Cancer Consortium  
(ILCCO) evaluating the association between various BMI variables and lung cancer 
overall survival (OS), reported as adjusted hazard ratios (aHR) from Cox proportional 
hazard models and adjusted penalized smoothing spline plots.  
Results: OS of NSCLC had putative U-shaped hazard ratio relationships with BMI, based 
on spline plots: being underweight (BMI<18.5-kg/m2; aHR=1.56; 95%CI:1.43-1.70) or 
morbidly overweight (BMI>40; aHR=1.09; 95%CI:0.95-1.26) at the time of diagnosis was 
associated with worse stage-specific prognosis, while being overweight (25≤BMI<30; 
aHR=0.89; 95%CI:0.85-0.95) or obese (30≤BMI≤40; aHR=0.86; 95%CI:0.82-0.91)) was 
associated with improved survival. Although not significant, a similar pattern was seen 
with SCLC. Compared with an increased or stable BMI from the time-period between 
young adulthood until date of diagnosis, a decreased BMI was associated with worse 
outcomes in NSCLC (aHR=1.24; 95%CI:1.2-1.3) and SCLC patients (aHR=1.26 
(95%CI:1.0-1.6). Decreased BMI was consistently associated with worse outcome, 
across clinico-demographic subsets. 
Conclusions: Both being underweight or morbidly obese at time of diagnosis is 
associated with lower stage-specific survival in independent assessments of NSCLC and 
SCLC patients. In addition, a decrease in BMI at lung cancer diagnosis relative to early 
adulthood is a consistent marker of poor survival. 
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Introduction 
The relationship between weight and cancer survival is complex. Being 
significantly obese or underweight may impair the efficacy of and tolerance to treatment. 
Examples include the impact of such extreme weight on surgical comorbidities (1–3) and 
when dosing chemotherapeutic agents (3–5). 
Obesity has long been associated with worse cancer outcomes. In the United 
States, being overweight was estimated to account for 14% of all cancer deaths in men 
and 20% in women, but this was studied in a cohort that was initially cancer-free, as 
opposed to a cohort of incident cancer patients; therefore, the reported mortality rates 
combined the effect of obesity on both cancer incidence and cancer outcomes (6). 
Obesity can cause systemic physiological alterations, such as higher insulin resistance, 
which has been linked to poor cancer outcomes (7), chronic inflammation (8), and 
abnormal nutrient homeostasis, which may lower the barrier for oncogenic transformation 
by driving cellular proliferation and resisting apoptosis (9). The American Society of 
Clinical Oncology has made investigation into the association of obesity with cancer one 
of its core initiatives in 2014, aiming to raise awareness of this relationship (10,11). Lung 
cancer stands apart from other solid tumors: in previous studies, an excess mortality due 
to obesity was not described for lung cancer; instead, overweight and obese patients had 
improved outcomes (6,12–19).  
In studies covering both resectable and metastatic lung cancers, the worst 
outcomes were observed in underweight patients, as defined by having a BMI<18.5, 
(6,12–15,20–29). Being severely underweight may be an indicator of cancer cachexia, 
which is a well described marker of poor outcome on cancer mortality (30–35). Weight in 
the years prior to lung cancer diagnosis has also been assessed. For example, a prior 
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case control study of 2,285 patients (16) reported no significant association between BMI 
at two years prior to lung cancer diagnosis and mortality, while a strong association was 
reported between BMI<18.5 at diagnosis and death; associations with temporal changes 
in BMI before diagnosis were not reported. 
There remain multiple key knowledge gaps in this research field, most commonly 
due to limited sample size and the single site nature of many published series. Firstly, as 
most published reports focused on non-small cell lung cancer (NSCLC), separate 
analyses of small cell lung cancer (SCLC) are scarce (36–39), while none have evaluated 
NSCLC and SCLC in parallel. Secondly, past studies have not assessed the role of 
morbid obesity (defined as BMI>40) on survival (17), but have focused on complication 
rates in both obese and morbidly obese patients (40,41). This is an important knowledge 
gap, as the only available data suggest that all overweight and obese patients have 
improved survival regardless of the magnitude of the BMI value. Thirdly, prior analyses 
have mostly assessed the prognostic role of BMI captured at the time of diagnosis, but 
have not evaluated BMI in a patients' prior healthy state. Although recent weight loss 
around the time of diagnosis has been associated with poor prognosis (21,32,35,42), 
longer term changes in BMI (i.e., from the time of young adulthood until diagnosis) have 
not been studied previously. Evaluation of BMI changes over a longer time may reflect 
metabolic or biologic effects that can both impact cancer risk and prognosis (7–9). 
In a large, multi-center, multi-national cohort, with special consideration of morbid 
obesity and SCLC patient subsets, we describe the prognostic association of three main 
BMI measurements: BMI at diagnosis, BMI at young adulthood (a surrogate for BMI when 
healthy), and change in BMI (DBMI) from a young adulthood to the time of diagnosis.  
 6 
Methods 
 
 Study population: The International Lung Cancer Consortium (ILCCO) was 
established in 2004 with the aims to share compatible data and maximize resource 
sharing for lung cancer epidemiology research. Full details have been provided 
previously (43) and are available at http://ilcco.iarc.fr. To be included in the present 
pooled analysis, studies had to have data on BMI at lung cancer diagnosis, lung cancer 
type (SCLC vs. NSCLC), date of diagnosis, stage at diagnosis, vital status at last follow 
up, and date of death. Optional variables included BMI at periods of time other than at 
diagnosis. The individual-level data across studies were then pooled, and checked for 
inconsistency, inadmissible values, aberrant distributions and outliers before being 
harmonized into a common data set. Written informed consents were obtained from all 
study participants, and each study was approved by its respective local institutional 
human subject review board.  
 Statistical analysis: Harmonization of epidemiological data elements has been 
previously described (44–48). Harmonization of outcomes-related variables are described 
in the Appendix. Separate analyses were performed for NSCLC and SCLC. OS was 
assessed using Kaplan–Meier curves and log-rank tests in univariable analyses. OS was 
assessed using penalized smoothing spline (PSS) curves (continuous BMI variable) and 
Cox proportional hazard models (continuous and categorical variables) in multivariable 
analyses, adjusting for clinically relevant factors identified in the univariable analyses (49, 
50). A detailed description of the PSS models is provided in the Appendix. Spline curves 
are functions that are defined piecewise by a polynomial, allowing complex shapes of 
relationships with continuous variables to be modeled. In addition to treating each BMI 
variable as a continuous variable, BMI at diagnosis and BMI during young adulthood 
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(defined as age 18-25) were also categorized into standard clinical groupings of <18 
kg/m2 (underweight), 18-<25 kg/m2 (normal weight), 25-<30 kg/m2 (overweight),  30-
≤40kg/m2 (obese) with the morbidly obese defined as >40kg/m2. Analyses were 
performed based on the pooled data, but subset analyses within individual studies were 
performed to evaluate consistency across studies. The clinical multivariable survival 
analysis that generated the base models included all variables with p-values less than 
0.05 on univariable analysis. To this base model, various definitions of BMI (BMI at 
diagnosis, BMI at young adulthood, DBMI), were added to the clinical multivariable model 
individually, as these variables were partially correlated; the association between BMI 
variables was tested using Pearson’s correlation test. Change in BMI (DBMI) from young 
adulthood to the time of diagnosis was used to correct partially for heterogeneity of 
baseline (pre-illness) BMI across the population, since it utilizes the same person's BMI at 
a prior, presumed healthy state (young adulthood) as a self-control. This study focuses 
on the primary relationships between BMI and survival; interaction analyses between BMI 
and other variables on survival will be reported in separate manuscripts.  
Sensitivity analyses were pre-planned to deal with potential issues related to study 
heterogeneity, including performing analyses that omitted participants/studies that had 
the following conditions, one at a time: the two SEER-staged studies; one study that used 
grade as a surrogate for stage, any single large studies that had over 15% of the total 
population, and individual participants who were originally staged before the A/B 
substages were incorporated into the staging system (conservatively estimated to be 
before the year 2000, as the 6th edition of the AJCC staging manual was released in 
1998). The fixed effect model was used when evaluating the impact of different study 
groups. Given that BMI norms may be different by race, sensitivity analyses by ethnicity 
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were performed that omitted any minority ethnicities that contributed over 15% of the total 
sample. 
 
 
Results 
 Patient and characteristics: A total of 29,217 patients met the inclusion criteria 
from the 16 studies and were included in the base (clinical) model analysis. Patient 
characteristics of the pooled population according to lung cancer type are shown in Table 
1: studies were from North America, Europe, and Asia; median age was 65 years; 54% 
were males; the majority were ever-smokers; 10% had SCLC and the most common 
NSCLC subtype was adenocarcinoma; overall median follow-up time was 3.9 years and 
71% patients had died during follow-up.  
 BMI at diagnosis was available for 79% of patients, while BMI before diagnosis 
was available for 22% of patients. Median BMI at diagnosis and young adulthood was 25 
and 23, respectively; the correlation between these two values was 0.46 (p<0.001). 
Supplementary Table 2 describes the median OS and median follow-up times by stage, 
demonstrating consistency with stage-specific expected median OS. 
 Patient characteristics and OS: The results of the univariable analysis for OS 
are summarized in Table 2. Higher cancer stage, being older, being male, and not 
graduating from high school were each associated with lower survival rates for both 
NSCLC and SCLC. Cumulative smoking exposure, squamous cell histology, recent year 
of diagnosis and being of African (black) ancestry were associated with lower survival 
rates for NSCLC. Multivariable analysis confirmed these variables as independently 
associated with survival (Table 2). Cumulative smoking was not included in the final 
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multivariable model due to missing data for a large number of patients (Table 2). 
However, results remained unchanged in the subgroup of patients with available 
cumulative smoking data (Supplementary Table 3).  
 Overall Survival (OS) and BMI at diagnosis, BMI in young adulthood, and 
change in BMI (DBMI) between these two time-points: Univariable and multivariable 
analyses of the association of BMI at a young adult age, BMI at diagnosis, and change in 
BMI with OS are shown in Table 2.  
 The association of BMI at diagnosis and OS is depicted in PSS curves adjusted for 
the clinical base model (Figure 1A, 1B, Table 2) and the unadjusted Kaplan-Meier 
survival curves (Figure 1C, 1D, Table 2). For patients with NSCLC (Figure 1A, 1C), there 
was a strong association with higher risk of death in underweight patients, when 
compared to normal weight individuals; risk of death was lowest in normal, overweight, 
and obese patients, but when the BMI was greater than 40 (morbid obesity), the risk of 
death increased again (Figure 1A, 1C, Table 2). For SCLC (Figure 1B, 1D), though there 
was no statistically significant association and the magnitude of HRs were smaller, the 
overall shape of HRs across different BMIs was similar to that of NSCLC with greater 
risks in the lowest and highest BMI groups (Figure 1B versus 1A; Table 2). Analysis of 
the association between BMI at diagnosis and lung-cancer free survival showed similar 
findings (Supplementary Figure 1), except for an attenuation of the increased risk of lung 
cancer specific death in morbidly obese individuals. 
 The corresponding associations between BMI in young adulthood and OS is 
shown in the PSS curves (Figure 2A, 2B), Kaplan-Meier survival curves (Figure 2C, 2D), 
and summarized in Table 2. There was no strong association between BMI in young 
adulthood and OS in NSCLC (Figure 2A, 2C; Table 2). However, there was a statistically 
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significant relationship between being underweight during young adulthood and having 
poorer survival after diagnosis with SCLC; this relationship is revealed in the multivariable 
analysis (Figure 2B, Table 2) that corrected for confounding prognostic variables, than in 
the univariable analysis (Figure 2D, Table 2).  
 The association between the change in BMI (DBMI) from early adulthood to the 
time of lung cancer diagnosis and OS is depicted in the PSS curves (Figure 3A, 3B), the 
Kaplan-Meier survival curves (Figure 3C, 3D), and summarized in Table 2. Relative to the 
BMI during early adulthood, a decrease in BMI at diagnosis was associated with worse 
OS when compared to patients who had similar or increased BMI at the time of diagnosis 
for patients with NSCLC; the benefit of an increase in BMI was present significantly for 
increases as large as DBMI of +12. There was a similar association in SCLC (Table 2, 
Figure 3B, 3D), except that the benefit of a stable/increased BMI only occurred up to 
DBMI of +6 (an increase of 6kg/m2 of BMI). Note that fewer than 10% of patients had a 
DBMI > +6, suggesting that the estimates above DBMI > +6 may be hard to interpret. 
 Subset Analyses and Sensitivity Analyses: Subset analyses of the individual 
studies confirmed that 15 of 16 individual studies reported that underweight patients had 
numerical HRs above unity, consistent with the pooled analysis.  
 When evaluating subset relationships between BMI at diagnosis and OS, BMI at 
young adulthood and DBMI (Supplementary Figures 2-4) by age, gender, education, 
smoking status, ethnicity, histology, and stage, the most consistent relationship seen 
across all subsets was observed with DBMI: a decrease in BMI was associated with an 
increase in risk of death in all subsets of NSCLC and in most subsets of SCLC (where 
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none of the subsets were associated with a decrease in risk). In contrast, both BMI at 
diagnosis and BMI in young adulthood showed much more heterogeneous associations. 
 The association between OS and BMI at diagnosis, in young adulthood, or 
changes in BMI prior to diagnosis remained similar across multiple pre-planned sensitivity 
analyses (Supplementary Table 3); these sensitivity analyses removed patients with data 
variables one-by-one and assessed whether the subsequent primary association 
remained similar after removal. Sensitivity studies confirmed consistency of the primary 
associations reported, despite minor variation in the magnitude of associations. 
 
Discussion 
This large pooled analysis identified a number of novel findings of the relationship 
between BMI variables measured in young adulthood, change prior to diagnosis and at 
the time of diagnosis, and lung cancer survival outcomes. We describe that DBMI, that is, 
a change in BMI between early adulthood and the diagnosis date, was associated with 
overall survival in lung cancer. Specifically, a decrease in BMI when compared to a 
remote time period at young adulthood is consistently associated with poorer lung cancer 
survival across age groups, gender, smoking status, stage, and histology with adjusted 
hazard ratios of approximately 1.25. Its consistency in association across many 
subgroups suggests its potential utility as a clinically useful global marker of lung cancer 
prognosis.  
We also report a potential U-shaped association between BMI at diagnosis and 
OS with greater mortality in the extreme groups of underweight and morbidly obese 
patients, relative to patients who are normal weight, with the best outcomes in those who 
are overweight or obese (but not morbidly obese). These relationships appear to be 
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similar between NSCLC and SCLC patients, but more pronounced in the NSCLC 
patients. Whereas the increase in mortality in the underweight lung cancer patients is 
consistent across all analyses, the increase in mortality in the morbidly obese lung cancer 
patients is not as clear: the number of morbidly obese patients is modest, and the 
relationship is attenuated when evaluating lung-cancer specific mortality. Thus, the 
increase in mortality in the morbidly obese patients may be due to non-lung cancer 
related causes, especially given the known increase in risk of death from all causes 
associated with morbid obesity. Our results also confirm findings in other patient cohorts 
that being overweight or obese at lung cancer diagnosis was associated with improved 
OS when compared to patients with normal BMI (6,12–19). The association between low 
BMI and lower OS rates have been described for several malignancies, including lung 
cancer, with similar effect size (6,12–15,20–29). However, the positive association 
between high BMIs between 25 and 40 and OS for NSCLC patients is contrary to the 
inverse association described for most other malignancies (6,10,51–53). The reasons for 
such findings in lung cancer remain unclear, but several biological explanations have 
been postulated. 
In a meta-analysis of over 10,000 patients, Zhu et al reported that increasing BMI 
is associated with lower lung cancer risk in never smokers, especially in women, raising 
questions whether estrogens play a protective role in lung cancer carcinogenesis; effects 
on prognosis were not studied (54). A gender difference in outcomes is suggested by our 
results: both low BMI at diagnosis and a decrease in DBMI appear to adversely affect 
overall survival to a greater extent in women than in men (Supplementary Figures 2 and 
4), indirectly suggesting a potential hormonal influence on survival. In exploratory 
analyses, these gender differences were not found to be ethnically driven (data not 
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reported), and are thus unlikely to be driven solely by molecular profiles (as Asian women 
have a much higher chance of carrying an epidermal growth factor receptor activating 
mutation).   
Biologically, the finding of similar prognostic relationships between BMI at 
diagnosis and DBMI in Asians is important (Supplementary Figures 2-4), as Asians 
diagnosed with NSCLC have different molecular profiles and outcomes compared to 
other ethnicities (55). Thus, our results suggest that these BMI-survival relationships 
transcend histomolecular subtype differences, although conclusive evidence would need 
to be based on molecular profiling data, which we do not have access to for this project.   
Dahlberg et al found a time-dependent relationship whereby obesity initially led to 
improved outcomes in stage IV patients treated with chemotherapy early in follow-up, but 
that the risk of death increased in obese patients after 16 months (13); a time-dependent 
analysis of our Stage IV patients did not confirm such an association in our sample (data 
not reported).    
In our pooled analysis, the relationships in both BMI at diagnosis and DBMI were 
consistent across different disease stages, including Stage IA patients who typically 
undergo only surgical resection, and stage IV patients, who typically undergo only 
systemic therapy. Such consistency suggests that either the effects of BMI on survival 
are treatment-independent, or that multiple treatments interact with BMI in a similar 
manner on survival outcomes. 
 Compared to normal BMI during early adulthood, a significantly worse prognosis in 
SCLC patients who were underweight during early adulthood was an unexpected finding, 
but must be interpreted with caution, given the small numbers of patients. Further, 
because of missing data, we were not able to account for cumulative smoking exposure 
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or comorbidities in this specific analysis. Where data were available, adjustment for 
smoking did not influence most results; the exception was a larger HR when comparing 
the underweight vs normal BMI patients at both diagnosis and in young adulthood, which 
was observed in both NSCLC and SCLC. These data suggest that it is possible that 
being underweight during early adulthood was also associated with heavier tobacco 
consumptions, which led to greater comorbidities at the time of diagnosis, and thus a 
worse prognosis; future analyses could attempt to quantify directly cumulative smoking 
exposure, and particularly intensity of smoking in early adulthood, and compare it OS 
after lung cancer diagnosis. 
 The relatively better OS in patients with BMI from 18.5 to 40, specifically in Stage 
II-IV patients, is reassuring from a chemotherapy dosing perspective, as the vast majority 
of patients will fall in this range of BMIs. Although there are data regarding the importance 
and safety of full dosing based on true body weight, some overweight/obese patients are 
still under-dosed based on an assumed ideal body weight, or a capped body surface area 
of 2m2 (56). While we had no dosing data for the patients included in this analysis, it is 
reassuring that OS for overweight patients is actually better than for those with BMI 
values within normal limits in patients with disease stages that are generally treated with 
chemotherapy. OS for patients with BMI≥40 were found to be worse comparable to 
patients with normal BMI. Whether this loss of the protective effect of high BMI represents 
the OS effect of comorbidities associated with higher BMI, suboptimal dosing or other 
factors is unknown. 
Our study has several limitations. First, the harmonization of different datasets 
collected in different countries and time periods, with lack of treatment data, might have 
introduced external bias, although multiple sensitivity analyses showed similar results. 
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Secondly, BMI data was derived from self-report data, a method known to be highly 
correlated with measured height and weight (57–59), with slight overestimation of height 
and underestimation of weight. Thus, reported BMI probably slightly underestimates true 
BMI values. Thirdly, BMI during early adulthood is also prone to recall bias and the 
reported changes may well have occurred recently, rendering DBMI a surrogate for recent 
weight loss. However, BMI at additional time-points between young adulthood and at 
diagnosis was unavailable for this analysis. That the association between DBMI and 
overall survival was observed consistently across stages, including Stage I and II 
NSCLCs where patients are least likely to be symptomatic from their cancer, suggests 
that the DBMI relationship is not completely attributable to recent weight loss as a 
symptom of the lung cancer.  Fourthly, the strength of the association between BMI and 
OS in the morbidly obese group is not as strong as the associations with underweight 
patients. Thus, the finding of adverse outcomes associate with morbid obesity is more 
preliminary in nature. Fifthly, the analysis did not include data on different lung cancer 
treatments, a potential confounding factor. It should be noted that some individual studies 
did provide treatment data, but when treatment and stage were included in the same 
model, there was significant collinearity such that either stage or treatment needed to be 
removed; since data for stage was complete whereas treatment data was limited, stage 
was ultimately left in the final models. Finally, some patients were excluded from the 
analysis due to missing data, potentially introducing additional selection bias.  
Recent data indicates that measures of body composition, capable of 
distinguishing muscle and fat, and a diagnosis of sarcopenia may be a better predictor for 
mortality in cancer (60–64). However, in the absence of data from these markers, as our 
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results suggest, changes in BMI from a healthy pre-morbid state may be a better 
prognosis surrogate than BMI at diagnosis.  
In summary, we identified a U-shaped relationship between BMI at diagnosis and 
OS in NSCLC patients, with the worst prognosis in underweight and morbidly obese 
patients. However, we also reported gender, ethnicity, and smoking heterogeneity in the 
prognostic relationship with BMI at diagnosis in our study. Thus, there should be caution 
regarding generalizing this relationship, given that each of these demographic variables 
can also influence baseline pre-morbid BMI. Instead, DBMI generated a more consistent 
prognostic relationship with OS across clinico-demographic groups: a decrease in DBMI 
from early adulthood to the time of diagnosis was associated with a modest, but 
significant 20-30% increase in risk of dying. 
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Figures 
Figure 1: The hazard ratio of overall survival based on penalized smoothing spline by 
body mass index at diagnosis (BMI, kg/m2) for (A) non-small cell lung cancer and (B) 
small cell lung cancer, and Kaplan Meier survival curves for (C) non-small cell lung 
cancers patients and (D) small cell lung cancer patients. Note that BMI data points above 
60 are sparse, explaining the wide confidence intervals in panels (A) and (B). DATA ARE 
SPARSE WHEN BMI>60, AND INTERPRETATION SHOULD BE MADE WITH CAUTION 
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Figure 2: The hazard ratio of overall survival based on penalized smoothing spline by 
body mass index at young adulthood (BMI, kg/m2) for (A) non-small cell lung cancer and 
(B) small cell lung cancer, and Kaplan Meier survival curves for (C) non-small cell lung 
cancers patients and (D) small cell lung cancer patients. Young adulthood is defined as 
an age between 18-25 years, or approximately 20 years. 
   
A B
C D
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Figure 3: The hazard ratio of overall survival based on penalized smoothing spline by 
change in body mass index at diagnosis (DBMI, kg/m2) for (A) non-small cell lung cancer 
and (B) small cell lung cancer, and Kaplan Meier survival curves for (C) non-small cell 
lung cancers patients and (D) small cell lung cancer patients. The change compares the 
relationship between BMI at young adulthood (around aged 20 years) to the BMI at the 
time of the diagnosis, as a means of correcting for heterogeneity of BMI in a healthy 
population. 
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Table 1: Patients characteristics according to lung cancer type 
 
Small cell lung cancer Non-Small Cell Lung Cancer 
Categories Variable # Studies providing 
data  
Summary Statistics 
# Studies 
providing 
data  
Summary Statistics 
16 2,787 (100%) 16 26,430 (100%) N (%) Total Counts 
16 65 (22-92) 16 65 (17-97) Median (range) Age, years 
16 2005 (1987-2015) 16 2006 (1974-2015) Median (range) Year of diagnosis 
16 1561 (56%) 16 14150 (54%) Males Sex, N (%) 
14 
Low: 220 (12%) 
High: 1,643 (88%) 
897 
14 
1,927 (11%) 
15,373 (89%) 
7558 
No 
Yes 
Missing 
High school 
graduate 
16 
2,484 (93%) 
59 (2%) 
33 (1%) 
98 (4%) 
113 
16 
18,141 (76%) 
3,938 (17%) 
1,020 (4%) 
686 (3%) 
2645 
Caucasian 
Asian 
Black 
Other 
Missing 
Ethnicity 
16 
- 
- 
- 
- 
- 
- 
- 
1,135 (41%) 
1,652 (59%) 
16 
5,478 (21%) 
2,448 (9%) 
1,131 (4%) 
1,884 (7%) 
3,905 (15%) 
2,434 (9%) 
9,150 (35%) 
- 
- 
1A 
1B 
2A 
2B 
3A 
3B 
4 
Limited Stage 
Extensive Stage 
Stage 
16 
- 
- 
- 
2,787 (100%) 
- 
16  
6,024 (23%) 
15,812 (60%) 
4,527 (17%) 
- 
67 
Squamous cell 
Adenocarcinoma 
Other 
Small cell 
Missing 
Histology 
14 
2389 (98%) 
54 (2%) 
57 
14  
17118 (84%) 
3201 (17%) 
3847 
Ever-smoker 
Never-smoker 
Missing 
Smoking Status 
13 50 (0.5-200) 748 13 
43 (0-275) 
6304 
Median (range) 
Missing 
Pack years among 
ever-smokers 
16 
26.3 (12-70) 
16 
25.2 (11-87) Median (range) BMI at diagnosis 
 65 (3%) 
765 (36%) 
815 (38%) 
 
487 (23%)a 
 
655 
906 (4%) 
9,189 (44%) 
7,086 (34%) 
3435 (16%) 
321 (2%) 
5493 
BMI<18.5 (underweight) 
18.5≥ BMI <25 (normal BMI) 
25≥ BMI <30 (overweight) 
 40 ≥ BMI ≥30 (obese) 
BMI ≥ 40 (morbidly obese) 
Missing 
7 
22.7 (14-43) 
7 
22.7 (10-71) Median (range) 
 BMI at young adult 
age 
31 (6%) 
398 (71%)  
95(17%) 
 
35 (6%)a 
  
134 
397 (7%) 
3518 (65%)  
1121 (21%) 
378 (7%)  
40 (1%) 
943 
BMI<18.5 (underweight) 
18.5 ≤ BMI <25 (normal BMI) 
25 ≤ BMI <30 (overweight) 
 30 ≤ BMI ≤ 40 (obese) 
BMI ≥ 40 (morbidly obese) 
Missing 
7 
112 (20%) 
442 (80%) 
139 
7 
1639 (30%) 
3790 (70%) 
968 
Decreased BMI 
No change/ Increased BMI 
Missing 
BMI change from 
young adult age to 
diagnosis 
athere were too few morbidly obese individuals to form its own category in small cell lung cancer; instead obese and 
morbidly obese were grouped together. 
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Table 2: Association between patient characteristics and overall survival: Univariable and Multivariable Analysis 
aThe multivariable base models included either 26,430 NSCLC or 2,787 SCLC patients with data on all assessed variables in the table; for multivariable analysis of Body Mass Index (BMI) at diagnosis, BMI at young adult 
age, and change in BMI from young adult age to time of diagnosis, each of these BMI variables was added individually to the multivariable base model. BMI at diagnosis was available for 20,937 NSCLC and 2,132 SCLC 
patients. BMI at young adult age was available for 5,454 NSCLC and 559 SCLC patients. Change in BMI was available for 5,429 NSCLC and 554 SCLC patients.  b for every 10 pack years smoked. Not included in the base 
multivariable model for NSCLC due missing data for 14,359 patients; c the year 2000 was chosen because it was the first full implementation year of AJCC 6th edition staging (published in 1998), which was significantly 
different than the 5th edition; the 4th and 5th edition are similar and the 6th and 7th edition are similar; d underweight, BMI < 18.5; normal weight 18.5 ≤ BMI <25; overweight 25 ≤ BMI <30; obese, 30 ≤ BMI ≤ 40; 
morbidly obese, BMI > 40. e for small cell lung cancer, there were not enough morbidly obese individuals to study separately, and the obese and morbidly obese categories were combined together 
Small Cell Lung Cancer (HR (95%CI), p-value Non-Small Cell Lung Cancer (HR (95%CI), p-value Comparisons Variable 
Multivariable Analysis Univariable analysis Multivariable analysisa Univariable analysis 
Base (clinical) model variables 
- 
- 
- 
- 
- 
- 
2.50 (2.3-27), <0.001 
- 
- 
- 
- 
- 
- 
2.50 (2.3-2.7), <0.001 
1.46 (1.35,1.58), <0.001 
1.60 (1.45,1.76), <0.001 
2.20 (2.04,2.38), <0.001 
3.15 (2.96,3.35), <0.001 
4.29 (4,4.59), <0.001 
7.55 (7.14,7.99), <0.001 
- 
1.52 (1.4-1.6), <0.001 
1.72 (1.6-1.9); <0.001 
2.36(2.2-2.5), <0.001 
3.40 (3.2-3.6), <0.001 
4.60 (4.3-4.9), <0.001 
7.79 (7.4-8.2), <0.001 
- 
1B vs 1A 
2A vs 1A 
2B vs 1A 
3A vs 1A 
3B vs 1A 
4 vs 1A 
Extensive vs Limited 
Stage 
1.28 (1.22-1.34), <0.001 1.30 (1.24-1.35), <0.001 1.20 (1.18-1.21), <0.001 1.21 (1.19-1.22), <0.001 per increase in 10 Age 
0.86 (0.79-0.93), <0.001 0.82 (0.76-0.89), <0.001 0.78 (0.75,0.8), <0.001 0.75 (0.73-0.77), <0.001 Female vs Male Sex 
0.82 (0.70-0.97), 0.02 0.72 (0.62-0.85), <0.001 0.84 (0.80-0.90), <0.001 0.77 (0.73-0.82), <0.001 Graduate vs Not Secondary school 
- 
1.12 (0.79-1.60), 0.53 
0.97 (0.63-1.50), 0.89 
0.92 (0.74-1.15), 0.48 
0.93 (0.84,1.03), 0.17 
1.11 (1.02-1.20), 0.02 
0.87 (0.80-0.96), 0.004 
0.86 (0.78-0.96), 0.005 
1.06 (0.97-1.20),  0.18   
0.83 (0.76-.91), <0.001 
Asian vs Caucasian 
Black vs Caucasian 
Other vs Caucasian 
Ethnicity 
-- 1.01 (1.00-1.03), 0.06 -- 1.04 (1.03-1.04), <0.001 per increase in 10 Pack yearsb 
-- 1.06 (0.95-1.18), 0.28                                                            -- 1.03 (0.98-1.07), 0.22 2000 onward vs. Before 2000 Year of diagnosisc 
Not applicable not applicable 0.80 (0.77-0.83), <0.001 1.03 (0.98-1.1), 0.24 
0.73 (0.70-0.76), <0.001 
0.95 (0.91-1.0), 0.04 
Adeno vs squam 
Other vs squam Histology 
BMI variables 
1.01 (0.97-1.06), 0.53 1.00 (0.96-1.04), 0.98 0.92 (0.91-0.94), <0.001 0.95 (0.93-0.96), <0.001 per increase of 5 
BMI at diagnosisd 
 
1.20 (0.92-1.6), 0.18 
0.93 (0.84-1.0), 0.20 
 
1.07 (0.95-1.2), 0.24e 
1.16 (0.89-1.51), 0.28 
0.97 (0.87-1.07), 0.51 
 
1.05 (0.94-1.19), 0.39e 
1.56 (1.43-1.70), <0.001 
0.89 (0.85-0.93), <0.001 
0.86 (0.82-0.91), <0.001 
1.09 (0.95-1.26),     0.22 
1.43 (1.32-1.55), <0.001 
0.94 (0.90-0.97), <0.001 
0.92 (0.88-0.97), <0.001 
1.04 (0.91-1.19),     0.56 
underweight vs normal 
overweight vs normal 
obese vs normal 
morbidly obese vs normal 
1.03 (0.9-1.2), 0.68 1.01 (0.89,1.14), 0.89 1 (0.96,1.05), 0.83 1.05 (1.01-1.09), 0.02 per increase of 5 
BMI at young adult 
aged 
1.93 (1.3-2.9), 0.001 
1.26 (0.98-1.6), 0.07 
 
1.39 (0.94-2.0), 0.10e 
1.70 (1.1-2.5), 0.009 
1.22 (0.95-1.6), 0.12 
 
1.22 (0.83-1.8), 0.30e 
1.15 (1-1.31), 0.04 
0.98 (0.9-1.07), 0.69 
1.07 (0.93-1.23), 0.33 
1.27 (0.88-1.84), 0.20 
1.06 (0.93-1.20), 0.38 
1.06 (0.97-1.15), 0.22 
1.16 (1.02-1.32), 0.03 
1.28 (0.88-1.85), 0.19 
underweight vs normal 
overweight vs normal 
obese vs normal 
morbidly obese vs normal 
1.03 (0.93-1.2), 0.57 1.03 (0.93-1.2), 0.55 0.89 (0.86-0.92), <0.001 0.87 (0.8-0.9), <0.001 per increase of 5 Change in BMI from 
young adult age to 
diagnosis 1.26 (1.0-1.6), 0.06 1.25 (1.0-1.6), 0.06 1.24 (1.2-1.3), <0.001 1.31 (1.2-1.4), <0.001 Decrease vs Increase/Stable 
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Supplementary Table 1: Characteristics of the included studies 
Study group Country Enrollment period, 
median (range) 
Original 
sample size 
Sample size included in 
analysis1 
Participation response 
rates of cases (%) 
CAPUA Spain 2003 (2000-2010) 862 862 91% 
CARET USA 1991 (1985-1994) 2,236 998 80% 
ESTHER Germany 2002 (2001-2004) 201 104 50% 
Fudan China 2012 (2009-2013) 1,913 1,806 95% 
Harvard USA 2004 (1992-2011) 3,411 3,411 83% 
Hawaii USA 1994 (1991-1997) 535 535 67% 
Japan Japan 2004 (1997-2008) 1,512 1,495 98% 
Karmanos USA 2002 (1999-2005) 913 890 52% 
LLP  England 2009 (1996-2013) 451 346 80% 
Los Angeles USA 2001 (1999-2003) 610 391 62% 
Mayo USA 2006 (1997-2014) 17,034 12,332 74% 
MD Anderson USA 2010 (2008-2012) 746 745 90% 
NIH USA 2006 (1993-2015) 1,699 1,479 40% 
ReSoLuCENT England 2009 (2001-2013) 545 545 33% 
TLC-Moffit USA 2011 (2001-2013) 744 744 82% 
Toronto Canada 2009 (1974-2013) 2,534 2,534 83% 
Total 2006 (1974-2015) 35,946 29,217  
 
1Patients were not included in the analysis if lung cancer type (small cell/non-small cell) or survival data were missing. NA: not available; SD: standard deviation.  
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Supplementary Table 2: Summary of Clinical Outcomes 
Type of 
Lung 
Cancer 
Stage N 
Median overall survival Median Survival Rates used for the 7th Edition AJCC1 Median Follow-up Time 
in years (months) (among 
censored patients) All patients in years (months) 
Patients diagnosed 
since 2000  
in years (months)  
Pathologic 
Staging in years 
(months) 
Clinical Staging 
in years 
(months) 
Non-small 
cell lung 
cancer 
All stages 26,430 2.3 (28)  2.3 (28) Not applicable Not applicable 3.9 years (47 months) 
1A 5,478 9.2 (110) 9.3 (112)  9.0 (119) 5.0 (60) 4.3 years (52 months) 
1B 2,448 7.1 (85) 7.4 (89) 6.8 (81) 3.6 (43) 4.8 years (58 months) 
2A 1,131 5.3 (63) 5.8 (69) 4.1 (49) 2.8 (34) 3.8 years (46 months) 
2B 1,884 3.3 (40)  3.3 (40) 2.6 (31) 2.8 (18) 4.0 years (48 months) 
3A 3,905 2.3 (28)  2.3 (30) 1.8 (22) 1.2 (14) 3.4 years (41 months) 
3B 2,434 1.4 (17) 1.4 (17) 1.1 (13) 0.8 (10) 3.2 years (28 months) 
4 9,150 0.9 (11)  0.9 (11) 1.4 (17) 0.5 (6) 2.4 years (29 months) 
Small cell 
lung cancer 
All stages 2,787 1.0 (12)  1.0 (12) Not applicable2 Not applicable 3.0 years (26 months) 
Limited stage 1,135 1.5 (18)  1.5 (18) Not applicable2 1- 2.5 (12-30) (IIIB-IA) 3.3 years (40 months) 
Extensive stage 1,652 0.8 (9)  0.8 (9) Not applicable2 0.7 (7) (IV) 1.8 years (22 months) 
 
1Goldstraw P, Crowley J, Chansky K et al (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage 
groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thoracic Oncol 2(8):706–714. 2 Small 
cell lung cancer patients are generally not resected; thus no pathologic staging is possible. 
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Supplementary Table 3: Sensitivity Analyses 
Exclusion of Patients 
diagnosed before 
the year 2000 
Exclusion of patients 
with no cumulative 
smoking datab 
Exclusion of Asian 
trials 
Exclusion of the 
single largest 
dataset 
Exclusion of trials 
with SEER staging 
data 
Exclusion of trial 
with no staging 
data 
Total Study Cohort Variable 
Non-Small Cell Lung Cancer 
14,065 15,489 19,667 12,073 21,671 22,599 22,950 N No. of patientsa 
0.98 (0.98-0.99) 
p<0.001 
0.98 (0.98-0.99) 
 p<0.001 
0.98 (0.98-0.99) 
p<0.001 
0.98 (0.97-0.98) 
p<0.001 
0.98 (0.98-0.99) 
p<0.001 
0.98 (0.98-0.99) 
 p<0.001 
0.98 (0.98-0.99) 
p<0.001 
HR
 (9
5%
CI
); 
p-
va
lu
e  
BMI at diagnosis, continuous 
variable 
1.57 (1.4-1.7) 
p<0.001 
1.62 (1.5-1.8) 
p<0.001 
1.58 (1.4-1.7) 
p<0.001 
1.47 (1.3-1.6) 
p<0.001 
1.52 (1.4-1.7) 
p<0.001 
1.57 (1.4-1.7) 
p<0.001 
1.56 (1.4-1.7) 
p<0.001 
Underweight vs 
Normal BMI; at diagnosis 
0.90 (0.85-0.94) 
p<0.001 
0.89 (0.85-0.94) 
p<0.001 
0.89 (0.85-0.93) 
p<0.001 
0.87 (0.83-0.92) 
p<0.001 
0.89 (0.85-0.93) 
p<0.001 
0.89 (0.85-0.93) 
p<0.001 
0.89 (0.85-0.93) 
p<0.001 
Overweight vs 
Normal BMI; at diagnosis 
0.89 (0.84-0.95) 
p<0.001 
0.89 (0.84-0.94) 
p<0.001 
0.88 (0.84-0.92) 
p<0.001 
0.83 (0.78-0.89) 
p<0.001 
0.88 (0.83-0.93) 
p<0.001 
0.88 (0.84-0.93) 
p<0.001 
0.88 (0.83-0.92) 
p<0.001 
Obese vs  
Normal BMI; at diagnosis 
1.00 (0.99-1.01) 
p=0.63 
1.00 (0.99-1.01) 
p=1.00 
1.00 (0.99-1.01) 
p=0.83 
1.00 (0.99-1.01) 
p=0.83 
1.00 (1.00-1.01) 
p=0.32 
1.00 (0.99-1.01) 
p=0.73 
1.00 (0.99-1.01) 
p=0.83 
BMI at young adulthood, 
continuous variable 
1.04 (0.9-1.21) 
p=0.59 
1.24 (1.04-1.48) 
p=0.02 
1.15 (1.0-1.31) 
p=0.04 
1.15 (1.0-1.31) 
p=0.04 
1.09 (0.94-1.25) 
p=0.25 
1.14 (0.99-1.3) 
p=0.07 
1.15 (1.0-1.31) 
p=0.042 
Underweight vs Normal BMI; in 
young adulthood 
0.95 (0.86-1.04) 
p=0.25 
0.97 (0.87-1.07) 
p=0.49 
0.98 (0.9,1.07) 
p=0.69 
0.98 (0.9-1.07) 
p=0.69 
0.96 (0.88-1.06) 
p=0.43 
0.99 (0.91-1.08) 
p=0.82 
0.98 (0.9-1.07) 
p=0.69 
Overweight vs Normal BMI; in 
young adulthood 
1.12 (0.97-1.29) 
p=0.13 
1.06 (0.92-1.22) 
p=0.43 
1.09 (0.96,1.24) 
p=0.20 
1.09 (0.96-1.24) 
p=0.20 
1.14 (0.99-1.3) 
p=0.07 
1.1 (0.96-1.25) 
p=0.16 
1.09 (0.96-1.24) 
p=0.20 
Obese vs Normal BMI; in young 
adulthood 
0.77 (0.71-0.84) 
p<0.001 
0.82 (0.75-0.90) 
p<0.001 
0.81 (0.75-0.87) 
p<0.001 
0.81 (0.75-0.87) 
p<0.001 
0.78 (0.72-0.84) 
p<0.001 
0.81 (0.75-0.88) 
p<0.001 
0.81 (0.75-0.87) 
p<0.001 
Increase in BMI vs 
 Decrease in BMI 
Small Cell Lung Cancer 
1,159 2,340 2,773 975 2,646 2,748 2,787 N No. of patientsa 
1.00 (0.99-1.01) 
p=0.88 
1.00 (0.99-1.01) 
p=0.52 
1.00 (0.99-1.01) 
p=0.52 
1.01 (0.99-1.02) 
p=0.43 
1.00  (0.99-1.01) 
p=0.5 
1.00 (0.99-1.01) 
p=0.63 
1 .00 (0.99-1.01) 
p=0.52 
HR
 (9
5%
CI
); 
p-
va
lu
e 
BMI at diagnosis, continuous 
variable 
1.20 (0.85-1.7) 
p=0.31 
1.17 (0.88-1.6) 
p=0.27 
1.17 (0.88-1.6) 
p=0.27 
1.18 (0.75-1.9) 
p=0.48 
1.2 (0.88-1.6) 
p=0.25 
1.17 (0.88-1.6) 
p=0.27 
1.17 (0.88-1.6) 
p=0.27 
Underweight vs Normal BMI; at 
diagnosis 
0.96 (0.84-1.1) 
p=0.60 
0.96 (0.86-1.1) 
p=0.44 
0.96 (0.86-1.1) 
p=0.44 
0.91 (0.76-1.1) 
p=0.28 
0.95 (0.85-1.1) 
p=0.39 
0.95 (0.85-1.1) 
p=0.44 
0.96 (0.86-1.1) 
p=0.44 
Overweight vs Normal BMI; at 
diagnosis 
1.02 (0.88-1.2) 
p=0.76 
1.07 (0.94-1.2) 
p=0.33 
1.07 (0.94-1.2) 
p=0.33 
1.1 (0.88-1.4) 
p=0.41 
1.07 (0.93-1.2) 
p=0.35 
1.07 (0.93-1.2) 
p=0.40 
1.07 (0.94-1.2) 
p=0.33 
Obese vs Normal BMI; at 
diagnosis 
1.01 (0.97-1.04) 
p=0.68 
1.01 (0.98-1.03) 
p=0.72 
1.01 (0.98-1.03) 
p=0.72 
1.01 (0.98-1.03) 
p=0.72 
1.01 (0.98-1.04) 
p=0.63 
1.00 (0.97-1.03) 
p=1 
1.01 (0.98-1.03) 
p=0.72 
BMI at young adulthood, 
continuous variable 
1.14 (0.57-2.27) 
p=0.71 
1.44 (0.87-2.39) 
p=0.16 
1.44 (0.87-2.39) 
p=0.16 
1.44 (0.87-2.39) 
p=0.16 
1.15 (0.58-2.3) 
p=0.69 
1.43 (0.84-2.41) 
p=0.18 
1.44 (0.87-2.39) 
p=0.16 
Underweight vs Normal BMI; in 
young adulthood 
1.07 (0.75-1.55) 
p=0.70 
1.10 (0.82-1.49) 
p=0.52 
1.10 (0.82-1.49) 
p=0.52 
1.10 (0.82-1.49) 
p=0.52 
1.12 (0.78-1.59) 
p=0.54 
1.03 (0.75-1.42) 
p=0.84 
1.10 (0.82-1.49) 
p=0.52 
Overweight vs Normal BMI; in 
young adulthood 
1.22 (0.77-1.94) 
p=0.39 
1.23 (0.8-1.91) 
p=0.35 
1.23 (0.80-1.91) 
p=0.35 
1.23 (0.80-1.91) 
p=0.35 
1.25 (0.79-1.99) 
p=0.34 
1.21 (0.78-1.87) 
p=0.40 
1.23 (0.80-1.91) 
p=0.35 
Obese vs Normal BMI; in young 
adulthood 
0.88 (0.63-1.2) 
p=0.48 
0.86 (0.65-1.1) 
p=0.28 
0.86 (0.65-1.1) 
p=0.33 
0.86 (0.65-1.1) 
p=0.28 
0.85 (0.61-1.2) 
p=0.33 
0.89 (0.66-1.2) 
p=0.42 
0.86 (0.65-1.1) 
p=0.28 
Increased/Stable BMI vs 
 Decreased BMI 
aAfter the exclusion of patients with missing data for the base multivariable model; bin this model, pack-years has been added to the model as a continuous predictor variable. 
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Supplementary Figure 1: Lung Cancer-Specific Survival: The hazard ratio of lung cancer free survival based on penalized smoothing 
spline by body mass index (BMI, kg/m2) at lung cancer diagnosis for non-small cell lung cancer
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Supplementary Figure 2: BMI at diagnosis (divided into categories) versus overall survival in subsets of patients defined by clinico-
demographic characteristics.  
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Supplementary Figure 3: BMI in young adulthood (divided into categories) versus overall survival in subsets of patients defined by 
clinico-demographic characteristics. 
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Supplementary Figure 4: Change in BMI from young adulthood until time of diagnosis versus overall survival in subsets of patients 
defined by clinico-demographic characteristics.  
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Appendix:  
Harmonization process  
 Patient data which required harmonization included education, which was dichotomized into whether they completed 
high school or not; and ethnicity, which was grouped as Caucasian, Black, Asian and other. NSCLC histology was grouped 
as adenocarcinoma, squamous cell carcinoma and other subtypes. BMI was calculated from metric or imperial height and 
weight values based on the available data, and grouped into BMI<18.5, 18.5≤BMI<25, 25≤BMI<30, and BMI≥30. BMI at 
young adulthood was defined as BMI at approximately 20 years of age (questionnaires from different studies requested that 
patients recall of their height and weight at ages from 18 years through 25 years). 
Cancer stage was harmonized as follows. Studies that provided TNM data were staged using the American Joint 
Committee on Cancer (AJCC), 7th edition, as the majority of patients were recruited when this edition was current. A 
sensitivity analysis according to year of diagnosis was pre-planned in order to account for any bias which might be created 
by using previous AJCC editions. Patients that lacked A/B substaging data were grouped with the substage "B" patients 
based on similarity of survival curves and proportions of patients surviving at 3- and 5-years. Two studies (Hawaii, 
Karmanos) provided only Surveillance, Epidemiology, and End Results Program (SEER) staging. Each SEER stage was 
harmonized with the AJCC stage with the most similar survival curves or proportions surviving at specific years. For 
NSCLC, SEER stages 1,2,3,4,7 were grouped with AJCC stages 1B, 2B, 3A, 3B and 4, respectively. For SCLC patients, 
SEER stages 1-4 were considered local disease (LD) while SEER stage 7 was considered extensive disease (ED). One 
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study (LA) provided disease grade data but had no stage data. Each grade group was combined the AJCC stage with the 
most similar survival curves; grades 1, 2 and 3 were harmonized with stages 1B, 3A and 4, respectively.  
Penalized smoothing spline (PSS) description 
The PSS models were fitted using pspline function and coxph function from survival package in R. They are 
penalized Cox PH models (Therneau and Grambsch, Modeling Survival Data: Extending the Cox Model, 2000, P120-123). 
The pspline function uses P-splines (Eilers and Marx, Statistical Science, 1981). The smoothing splines of BMI were plotted 
using multivariable models which included the same adjusted covariates in Table 2. The knots are determined by the 
degrees of freedom in this package. We tried different degrees of freedom to plot the splines and decided to use the default 
degrees of freedom, i.e. 4. The results were robust. 
  
